From traditional european medicine to discovery of new drug candidates for the treatment of dementia and alzheimer's disease: Acetylcholinesterase inhibitors

Current Medicinal Chemistry

Volumn 20, Issue 8, 2013, Pages 976-983

  Russo, P ^a   Frustaci, A ^a   Bufalo, A Del ^a   Fini, M ^a   Cesario, A ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Arnica chamissonis; Clinical trials; Drug discovery and development; European traditional medicine; Galanthamine; Melissa species; Ruta graveolens; Salvia officinalis; Systems biology

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARNICA; ARNICA CHAMISSONIS; ARTICLE; DRUG BINDING; MELISSA OFFICINALIS; MEMORY; NEUROPROTECTION; RUTA GRAVEOLENS; RUTACEAE; SALVIA OFFICINALIS; TRADITIONAL MEDICINE;

EID: 84877966990     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320080002     Document Type: Article

References (110)

1. http://whqlibdoc.who.int/publications/2012/9789241564458-eng.pdf (Accessed October 25, 2012).
2. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet, 2011, 377, 1019-1031.
3. Bartus, R.T.; Dean, R.L.III; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-417. (Pubitemid 12048290)
4. Dumas, J.A.; Newhouse, P.A. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol. Biochem. Behav., 2011, 99, 254-261.
5. Contestabile, A. The history of the cholinergic hypothesis. Behav. Brain Res., 2011, 221, 334-340.
6. Schliebs, R.; Arendt, T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res., 2011, 221, 555-563.
7. Podoly, E.; Shalev, D.E.; Shenhar-Tsarfaty, S.; Bennett, E.R.; Ben Assayag, E.; Wilgus, H.; Livnah, O.; Soreq, H. The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J. Biol. Chem., 2009, 284, 17170-17179.
8. Soreq, H.; Seidman, S. Acetylcholinesterase-new roles for an old actor. Nat. Rev. Neurosci., 2001, 2, 294-302.
9. Greenberg, D.S.; Toiber, D.; Berson, A.; Soreq, H. Acetylcholinesterase variants in Alzheimer's disease: from neuroprotection to programmed cell death. Neurodegener. Dis., 2010, 7, 60-63.
10. Hanin, G; Soreq, H. Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol. Neurosci., 2011, 4, 28.
11. Auld, D.S.; Kornecook, T.J.; Bastianetto, S.; Quirion, R. Alzheimer's disease and the basal forebrain cholinergic system: relations to-Amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol., 2002, 68, 209-245. (Pubitemid 35346805)
12. Picciotto, M.R.; Zoli, M. Nicotinic receptors in aging and dementia. J. Neurobiol., 2002, 53, 641-655. (Pubitemid 35375593)
13. Mufson, E.J.; Counts, S.E.; Fahnestock, M.; Ginsberg, S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr. Alzheimer Res., 2007, 4, 340-350. (Pubitemid 47416626)
14. Goekoop, R.; Scheltens, P.; Barkhoh, F.; Rombouts, S.A.R.B. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation -A pharmacological fMRI study. Brain, 2006, 129, 141-157. (Pubitemid 43063766)
15. Parri, R.H.; Dineley, T.K. Nicotinic acetylcholine receptor interaction with beta-Amyloid: molecular, cellular, and physiological consequences. Curr. Alzheimer Res., 2010, 7, 27-39.
16. Parri, H.R.; Hernandez, C.M.; Dineley, K.T. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem. Pharmacol., 2011, 2, 931-942.
17. Akaike, A.; Takada-Takatori, Y.; Kume, T.; Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J. Mol. Neurosci., 2010, 40, 211-216.
18. Takada-Takatori, Y.; Kume, T.; Ohgi, Y.; Fujii, T.; Niidome, T.; Sugimoto, H.; Akaike, A. Mechanisms of alpha7-nicotinic receptor up-regulation and sensitization to donepezil induced by chronic donepezil treatment. Eur. J. Pharmacol., 2008, 590, 150-156.
19. Takada-Takatori, Y.; Kume, T.; Ohgi, Y.; Izumi, Y.; Niidome, T.; Fujii, T.; Sugimoto, H.; Akaike, A. Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil. J. Neurosci. Res., 2008, 86, 3575-3583.
20. Bond, C.E.; Zimmermann, M.; Greenfield, S.A. Upregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides. PLoS ONE, 2009, 4, e4846.
21. Huang, Y.; Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell, 2012, 148, 1204-1222.
22. Cameron, B.; Landreth, G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis., 2010, 37, 503-509.
23. Wee Yong, V. Inflammation in neurological disorders: a help or a hindrance? Neuroscientist, 2010, 16, 408-420
24. Eikelenboom, P.; van Exel, E.; Hoozemans, J.J.; Veerhuis, R.; Rozemuller, A.J.; van Gool, W.A. Neuroinflammation -An early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener. Dis., 2010, 7, 38-41.
25. Shaked, I.; Meerson, A.; Wolf, Y.; Avni, R.; Greenberg, D.;, Gilboa-Geffen, A.; Soreq, H. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity, 2009, 31, 965-973.
26. Gilboa-Geffen, A.; Hartmann, G.; Soreq, H. Stressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions. Front Mol. Neurosci., 2012, 5, 30.
27. Nicolussi, E.M.; Huck, S.; Lassmann, H.; Bradl, M. The cholinergic antiinflammatory system limits T cell infiltration into the neurodegenerative CNS, but cannot counteract complex CNS inflammation. Neurobiol. Dis., 2009, 35, 24-31.
28. Herrmann, N.; Chau, S.A.; Kircanski, I.; Lanctot, K.L. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs, 2011, 71, 2031-2065.
29. Karenberg, A.; Förstl, H. Dementia in the Greco-Roman world. J. Neurol. Sci., 2006, 244, 5-9.
30. Wilmo, A.; Prince, M. World Alzheimer report 2010: the global economic impact of dementia. Alzheimer's Disease International. (Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf)
31. Wimo, A, Jönsson, L.; Gustavsson, A.; McDaid, D.; Ersek, K.; Georges, J.; Gulácsi, L.; Karpati, K.; Kenigsberg, P, .; Valtonen, H. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int. J. Geriatr. Psychiatry., 2011, 26, 825-832.
32. http://www.dementia2010.org/reports/Dementia2010Full.pdf. (Accessed October 25, 2012).
33. Getsios, D.; Blume, S.; Ishak, K.J.; Maclaine, G.D. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. Pharmacoeconomic., 2010, 28, 411-427.
34. Loy, C.; Schneider, L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev., 2006, 25, CD001747
35. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev., 2006, 25, CD005593.
36. Birks, J.; Grimley, Evans. J.; Iakovidou, V.; Tsolaki, M.; Holt, F.E. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev., 2009, CD001191.
37. http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm (Accessed October 25, 2012).
38. Wilkinson, D.; Schindler, R.; Schwam, E.; Waldemar, G.; Jones, R.W.; Gauthier, S.; Lopez, O.L.; Cummings, J.; Xu, Y.; Feldman, H.H. Effectiveness of donepezil in reducing clinical worsening in patients with mild-To-moderate alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2009, 28, 244-251.
39. Birks, J.; Harvey, R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev., 2006, 25, CD001190.
40. "Exelon". Yissum Technology Transfer. http://www.yissum.co.il/ success. php?cat=12&in=0. (Accessed October 25, 2012).
41. Desai, A.; Grossberg, G. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert Opin. Pharmacother., 2001, 2, 653-666. (Pubitemid 32427759)
42. Bailey, J.A.; Lahiri, D.K. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J. Neurochem., 2010, 112, 843-853.
43. Arrell, D.K.; Terzic, A. Network systems biology for drug discovery. Clin. Pharmacol. Ther., 2010, 88, 120-125.
44. Schmitz, R. Friedrich Wilhelm Sertürner and the discovery of morphine. Pharm. Hist., 1985, 27, 61-74.
45. Ignelzi, R.J.; Atkinson, J.H. Pain and its modulation. Part 2. Efferent mechanisms. Neurosurgery, 1980, 6, 584-590. (Pubitemid 10116010)
46. http://www.news-medical.net/health/Morphine-History.aspx. (Accessed October 25, 2012).
47. http://www.who.int/medicines/areas/traditional/definitions/en/index.html. (Accessed October 25, 2012).
48. Adams, M.; Gmünder, F.; Hamburger, M. Plants traditionally used in age related brain disorders-A survey of ethnobotanical literature. J. Ethnopharmacol., 2007, 113, 363-381. (Pubitemid 47361572)
49. Soloway, S.B. Naturally occurring insecticides. Environ. Health Perspect., 1976, 14, 109-117.
50. Anekonda, T.S.; Reddy, P,H. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res. Brain Res. Rev., 2005, 50, 361-376. (Pubitemid 41654401)
51. Chaiyana, W.; Okonogi, S. Inhibition of cholinesterase by essential oil from food plant. Phytomedicine, 2012, 19, 836-839.
52. dos Santos-Neto, L.L.; de Vilhena Toledo, M.A.; Medeiros-Souza, P.; G.A.; de Souza. The Use of Herbal Medicine in Alzheimer's Disease-A Systematic Review. Evid. Based Complement Alternat. Med., 2006, 3, 441-445. (Pubitemid 44899981)
53. Eckert, G.P. Traditional used Plants against Cognitive Decline and Alzheimer Disease. Front Pharmacol., 2010, 1, 138.
54. Ferreira, A.; Proença, C.; Serralheiro, M.L.; Araújo, M.E. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. J. Ethnopharmacol., 2006, 108, 31-37. (Pubitemid 44498982)
55. Houghton, P.J.; Howes, M.J. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease, Neurosignals, 2005, 14, 2-22.
56. Howes, M.J.; Perry, E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging, 2011, 28, 439-468.
57. Howes, M.J.; Perry, N.S.; Houghton, P.J. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res., 2003, 17, 1-18. (Pubitemid 36205453)
58. Ji, H.F.; Zhang, H.Y. Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol. Sin., 2008, 29, 143-151.
59. Kim, H.G.; Oh, M.S. Herbal medicines for the prevention and treatment of Alzheimer's disease. Curr. Pharm. Des., 2012, 18, 57-75.
60. Man, S.C.; Durairajan, S.S.; Kum, W.F.; Lu, J.H.; Huang, J.D.; Cheng, C.F.;, Chung, V.; Xu, M.; Li, M. Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease. J. Alzheimers Dis., 2008, 14, 209-223. (Pubitemid 352040038)
61. Orhan, I.; Sener, B.; Choudhary, M.I.; Khalid, A. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J. Ethnopharmacol., 2004,91, 57-60. (Pubitemid 38270227)
62. Park, S.Y. Potential therapeutic agents against Alzheimer's disease from natural sources. Arch. Pharm. Res., 2010, 33, 1589-1609.
63. Perry, E.; Howes, M.J. Medicinal plants and dementia therapy: herbal hopes for brain aging? CNS Neurosci. Ther., 2011, 17, 683-698.
64. Perry, N.; Court, G.; Bidet, N.; Court, J.; Perry, E. European herbs with cholinergic activities: potential in dementia therapy. Int. J. Geriatr. Psychiatr., 1996, 11, 1063-1069. (Pubitemid 27029813)
65. Wszelaki, N.; Kuciun, A.; Kiss A.K. Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity. Acta Pharm., 2010, 60, 119-128.
66. Georgiev, M.I. Editorial: Coming back to nature: plants as a vital source of pharmaceutically important metabolites. Curr. Med. Chem., 2012, 19, 2059-2060.
67. Orhan, I.E. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer's disease. Curr. Med. Chem., 2012, 19, 2252-2261.
68. Plaitakis, A.; Duvoisin, R.C. Homer's moly identified as Galanthus nivalis L.: physiologic antidote to stramonium poisoning. Clin. Neuropharmacol., 1983, 6, 1-5. (Pubitemid 13134999)
69. Heinrich, M.; Lee, T.H. Galanthamine from snowdrop-The development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J. Ethnopharmacol., 2004, 92, 147-162. (Pubitemid 38610095)
70. Heinrich, M. Galanthamine from Galanthus and other Amaryllidaceae- chemistry and biology based on traditional use. Alkaloids Chem. Biol., 2010, 68, 157-165.
71. Lopez, S.; Bastida, J.; Viladomat, F.; Codina, C. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sci., 2002, 71, 2521-2529. (Pubitemid 35247960)
72. Berkov, S.; Evstatieva, L.; Popov, S. Alkaloids in Bulgarian Pancratium maritimum. L. Z Naturforsch., 2004, 59c, 65-69.
73. Georgiev, V.; Ivanov, I.; Berkov, S.; Pavlov, A. Alkaloids biosynthesis by Pancratium maritimum L. shoots in liquid culture. Acta Physiol. Plant., 2011, 33, 927-933.
74. Schumann, A.; Berkov, S.; Claus, D.; Gerth, A.; Bastida, J.; Codina, C. Production of galanthamine by Leucojum aestivum shoots grown in different bioreactor systems. Appl. Biochem. Biotechnol., 2012, 167, 1907-1920.
75. Ivanov, I.; Georgiev, V.; Berkov, S.; Pavlov, A. Alkaloid patterns in Leucojum aestivum shoot culture cultivated at temporary immersion conditions. J. Plant Physiol., 2012, 169, 206-211.
76. Ivanov, I.; Georgiev, V.; Georgiev, M.; Ilieva, M.; Pavlov, A. Galanthamine and related alkaloids production by Leucojum aestivum L. shoot culture using a temporary immersion technology. Appl. Biochem. Biotechnol., 2011, 163, 268-277.
77. Mashkovsky, M.D.; Kruglikova-Lvova, R.P. On the pharmacology of the new alkaloid galantamine. Farmakologia Toxicologia (Moscow), 1951, 14, 27-30.
78. Thomsen, T.; Bickel, U.; Fischer, J.P.; Kewitz, H. Stereoselectivity of cholinesterase inhibition by galantamine and tolerance in humans. Eur. J. Clin. Pharm., 1990, 39, 603-605.
79. Samochocki, M.; Höffle, A.; Fehrenbacher, A.; Jostock, R.; Ludwig, J.; Christner, C.; Radina, M.; Zerlin, M.; Ullmer, C.; Pereira, E.F.; Lübbert, H.;, Albuquerque, E.X.; Maelicke, A Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther., 2003, 305, 1024-1036. (Pubitemid 36617980)
80. Samochocki, M.; Zerlin, M.; Jostock, R.; Kormelink, P.J.G.; Luyten, W.H.M.L.; Albuquerque, E.X.; Maelicke, A. Galantamine is an allosterically potentiating ligand of the human-4-2 nAChR. Acta Neurol. Scand., 2000, 176, 68-73. (Pubitemid 32156173)
81. Monod, J.; Wyman, J.; Changeux, J.P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol., 1965, 12, 88-118.
82. Taly, A.; Corringer, P.J.; Guedin, D.; Lestage. P.; Changeux, J.P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov., 2009, 8, 733-750.
83. Russo, P.; Taly. A.-7-Nicotinic acetylcholine receptors: an old actor for new different roles. Curr. Drug Targets, 2012, 13, 574-578.
84. Ludwig, J.; Höffle-Maas, A.; Samochocki, M.; Luttmann, E.; Albuquerque, E.X.; Fels, G.; Maelicke, A. Localization by site-directed mutagenesis of a galantamine binding site on-7 nicotinic acetylcholine receptor extracellular domain. J. Recept. Signal Transduct. Res., 2010, 30, 469-483.
85. Pereira, E.F.R.; Alkondon, M.; Reinhardt, S.; Maelicke, A.; Peng, X.; Lindstrom, J.; Whiting, P.; Albuquerque, E.X. Physostigmine and galanthamine: probes for a novel binding site on the-4-2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther., 1994, 270, 768-778. (Pubitemid 24271394)
86. Bond, M.; Rogers, G.; Peters, J.; Anderson, R.; Hoyle, M.; Miners, A.; Moxham, T.; Davis, S.; Thokala, P.; Wailoo, A.; Jeffreys, M.; Hyde, C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol. Assess, 2012, 16, 1-470.
87. Loveman, E.; Green, C.; Kirby, J.; Takeda, A.; Picot, J.; Payne, E.; Clegg, A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol. Assess, 2006, 10.
88. Kavanagh, S.; Gaudig, M.; Van Baelen, B.; Adami, M.; Delgado, A.; Guzman, C.; Jedenius, E.; Schäuble, B. Galantamine and behavior in Alzheimer disease: analysis of four trials. Acta Neurol. Scand., 2011, 124, 302-308.
89. Gaudig, M.; Richarz, U.; Han, J.; Van Baelen, B.; Schäuble, B. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Curr. Alzheimer Res., 2011, 8, 771-780.
90. Scarpini, E.; Bruno, G.; Zappalá, G.; Adami, M.; Richarz, U.; Gaudig, M.; Jacobs, A.; Schäuble, B. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J. Alzheimers Dis., 2011, 26, 211-220.
91. Van Puyvelde, K.; Mets, T. RODOS Study Group. Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population. Geriatr. Gerontol. Int., 2011, 11, 256-261.
92. Wallin, A.K.; Wattmo, C.; Minthon, L. Galantamine treatment in Alzheimer's disease: response and long-Term outcome in a routine clinical setting. Neuropsychiatric Dis. Treat, 2011, 7, 565-576.
93. Keller, C.; Kadir, A.; Forsberg, A.; Porras, O.; Nordberg, A. Long-Term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. J. Alzheimers Dis., 2011, 24, 109-123.
94. Grieve, M. A Modern Herbal. Leyel C.F. Ed. Penguin Handbooks [Paperback], 1980, pp. 700-705.
95. Perry, N.S.; Houghton, P.J.; Theobald, A.; Jenner, P.; Perry, E.K. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J. Pharm. Pharmacol., 2000, 52, 895-902. (Pubitemid 30461925)
96. Savelev, S.; Okello, E.; Perry, N.S.; Wilkins, R.M.; Perry, E.K. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol. Biochem. Behav., 2003, 75, 661-668. (Pubitemid 36936900)
97. Kennedy, D.O.; Dodd, F.L.; Robertson, B.C.; Okello, E.J.; Reay, J.L.; Scholey, A.B.; Haskell, C.F. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J. Psychopharmacol., 2011, 25, 1088-1100.
98. Scholey, A.B.; Tildesley, N.T.; Ballard, C.G.; Wesnes, K.A.; Tasker, A.; Perry, E.K.; Kennedy, D.O. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. J. Psychopharmacol., 2008, 198, 127-139.
99. Tildesley, N.T.; Kennedy, D.O.; Perry, E.K.; Ballard, C.G.; Savelev, S.; Wesnes, K.A.; Scholey, A.B. Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol. Biochem. Behav., 2003, 75, 669-674. (Pubitemid 36936901)
100. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther., 2003, 28, 53-59. (Pubitemid 36313176)
101. Coghan, T. The Haven of Health. Henrie Midleton, 1584, London.
102. Evelyn, J. Acetaria. Printed for B. Tooke, 1699, London.
103. Dastmalchi, K.; Ollilainen, V.; Lackman, P.; Boije af Gennäs, G.; Dorman, H.J.; Järvinen, P.P.; Yli-Kauhaluoma, J.; Hiltunen, R. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg. Med. Chem., 2009, 17, 867-871.
104. Burns, A.; Perry, E.; Holmes, C.; Francis, P.; Morris, J.; Howes, M.J.; Chazot, P.; Lees, G.; Ballard, C. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2011, 31, 158-164.
105. Brøndegaard, V.J. Folk og Flora, Dansk Etnobotanik, vols. I-IV. Rosenkilde og Bagger, Copenhagen, Denmark. 1978.
106. Adsersen, A.; Kjølbye, A.; Dall, O.; Jäger, A.K. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava. J. Ethnopharmacol., 2007, 113, 179-182. (Pubitemid 47077855)
107. Rollinger, J.M.; Schuster, D.; Danzl, B.; Schwaiger, S.; Markt, P.; Schmidtke, M.; Gertsch, J.; Raduner, S.; Wolber, G.; Langer, T.; Stuppner, H. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med., 2009, 75, 195-204.
108. http://www.who.int/mediacentre/factsheets/fs134/en/. (Accessed, October 25, 2012).
109. Thomas, K.J.; Nicholl, J.P.; Coleman, P.. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther. Medicine, 2001, 9, 2-11. (Pubitemid 32203876)
110. Rishton, G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today, 1997, 2, 382-384. (Pubitemid 27368216)